<DOC>
	<DOCNO>NCT02906605</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity JNJ-809 combine apalutamide improve compare apalutamide alone subject metastatic castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>A Study Clinical Activity Safety JNJ-64041809 , Live Attenuated Listeria Monocytogenes Immunotherapy , Combination With Apalutamide Versus Apalutamide Subjects With Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<criteria>Adenocarcinoma prostate Metastatic disease document technetium99m ( 99mTc ) bone scan metastatic lesion compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan Surgically medically castrate , testosterone level less ( &lt; ) 50 nanogram per deciliter ( ng/dL ) Castrationresistant prostate cancer document time prostatespecific antigen ( PSA ) increase continuous treatment androgen deprivation therapy ( ADT ) OR radiographic progression soft tissue OR radiographic progression bone accord PCWG3 Predominately small cell neuroendocrine carcinoma prostate Known brain metastasis ( even treat ) untreated epidural spread Prior chemotherapy prostate cancer , except administer adjuvant/neoadjuvant setting , 6 cycle docetaxel metastatic hormonesensitive prostate cancer Treatment medication know low seizure threshold investigational agent discontinue substitute great equal ( &gt; = ) 28 day prior randomization</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>